Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate
resistant prostate cancer when using conventional imaging. However, it is estimated that >90%
of patients have disease apparent when using PSMA PET. This study investigates the use of
local consolidation radiotherapy in this cohort of men.
Phase:
Phase 2
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)